# Regulatory Differences Between US and International Compounding

Canonical source: https://retacompare.com/research/us-vs-international-compounding-28

Compounded Peptides · 2026-04-08


    Compounding pharmacy regulation differs significantly between jurisdictions. In the European Union, compounded 'magistral' and 'officinal' preparations are regulated primarily at the member state level under Directive 2001/83/EC, with narrower scope than US compounding. In the UK, compounding for named patients is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Several Latin American and Asian jurisdictions allow broader compounding activities than either the US or EU. International arbitrage — US patients obtaining compounded GLP-1 products from Mexican or Caribbean pharmacies — has grown through 2025–2026 and sits in a legal gray area complicated by import laws and personal-use exceptions.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources